
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2790133/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tuberculosis. Lancet, The, 2019, 393, 1642-1656.	6.3	523
2	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respiratory Medicine,the, 2017, 5, 291-360.	5.2	459
3	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	6.3	257
4	Nanotechnology approaches for global infectious diseases. Nature Nanotechnology, 2021, 16, 369-384.	15.6	232
5	Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 536-544.	4.6	106
6	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2018, 15, e1002591.	3.9	96
7	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	5.2	92
8	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal, 2016, 48, 938-943.	3.1	71
9	Tuberculosis in times of COVID-19. Journal of Epidemiology and Community Health, 2022, 76, 310-316.	2.0	64
10	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1300-1310.	2.5	61
11	Challenges and controversies in childhood tuberculosis. Lancet, The, 2019, 394, 967-978.	6.3	54
12	Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India. PLoS ONE, 2013, 8, e68869.	1.1	51
13	The clinical management of drug-resistant tuberculosis. Current Opinion in Pulmonary Medicine, 2007, 13, 212-217.	1.2	50
14	Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. European Respiratory Journal, 2018, 51, 1800017.	3.1	39
15	Tuberculosis innovations mean little if they cannot save lives. ELife, 2017, 6, .	2.8	39
16	Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis. Emerging Infectious Diseases, 2016, 22, .	2.0	38
17	A gastric resident drug delivery system for prolonged gram-level dosing of tuberculosis treatment. Science Translational Medicine, 2019, 11, .	5.8	38
18	Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. International Journal of Infectious Diseases, 2015, 32, 56-60.	1.5	36

#	Article	IF	CITATIONS
19	"A very humiliating illness― a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa. BMC Public Health, 2020, 20, 76.	1.2	34
20	Peripheral neuropathy in persons with tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2016, 2, 5-11.	0.6	31
21	The Role of Traditional Healers in Community-Based HIV Care in Rural Lesotho. Journal of Community Health, 2011, 36, 849-856.	1.9	27
22	How COVID-19 could benefit tuberculosis and HIV services in South Africa. Lancet Respiratory Medicine,the, 2020, 8, 844-846.	5.2	27
23	Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clinical Infectious Diseases, 2021, 73, e3563-e3571.	2.9	23
24	Eliminating the categoryÂll retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bulletin of the World Health Organization, 2012, 90, 63-66.	1.5	22
25	Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?. PLoS ONE, 2015, 10, e0144936.	1.1	21
26	Advances in the diagnosis, treatment, and prevention of tuberculosis in children. Expert Review of Respiratory Medicine, 2019, 13, 301-311.	1.0	19
27	Outbreak of multidrug-resistant tuberculosis on Daru Island. Lancet Respiratory Medicine,the, 2016, 4, 347-349.	5.2	17
28	Pan-tuberculosis regimens: an argument against. Lancet Respiratory Medicine,the, 2018, 6, 240-242.	5.2	17
29	Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 441-450.	2.0	16
30	Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa. EClinicalMedicine, 2020, 20, 100290.	3.2	14
31	Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal of Clinical Microbiology, 2022, 60, jcm0236221.	1.8	14
32	The Impact of Tuberculosis on the Well-Being of Adolescents and Young Adults. Pathogens, 2021, 10, 1591.	1.2	13
33	Revising the definition of extensively drug-resistant tuberculosis. Lancet Respiratory Medicine,the, 2018, 6, 893-895.	5.2	12
34	Quality of drug-resistant tuberculosis care: Gaps and solutions. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 16, 100101.	0.6	11
35	Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic. The Lancet Child and Adolescent Health, 2021, 5, 159-161.	2.7	11
36	An update on repurposed medications for the treatment of drug-resistant tuberculosis. Expert Review of Clinical Pharmacology, 2016, 9, 1331-1340.	1.3	10

#	Article	IF	CITATIONS
37	Update in Tuberculosis/Pulmonary Infections 2015. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 142-146.	2.5	10
38	Treatment of Multidrug-resistant Tuberculosis Infection in Children. Pediatric Infectious Disease Journal, 2018, 37, 831-834.	1.1	10
39	Making the case: developing innovative adherence solutions for the treatment of tuberculosis. BMJ Global Health, 2019, 4, e001323.	2.0	10
40	Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?. Lancet Infectious Diseases, The, 2017, 17, e429-e433.	4.6	9
41	Drug-resistant tuberculosis: will grand promises fail children and adolescents?. The Lancet Child and Adolescent Health, 2018, 2, 237-238.	2.7	9
42	Treatment of Multidrug-Resistant Tuberculosis Infection in Children. Pediatric Infectious Disease Journal, 2018, 37, 1061-1064.	1.1	9
43	Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative?. Lancet Respiratory Medicine,the, 2019, 7, 999-1000.	5.2	9
44	The STREAM trial: missed opportunities and lessons for future clinical trials. Lancet Infectious Diseases, The, 2019, 19, 351-353.	4.6	9
45	Universal regimens or universal access to drug susceptibility testing for tuberculosis?. Lancet Infectious Diseases, The, 2019, 19, 224-225.	4.6	9
46	Preventing tuberculosis in children: A global health emergency. Paediatric Respiratory Reviews, 2020, 36, 44-51.	1.2	9
47	Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. Lancet Microbe, The, 2021, 2, e584-e593.	3.4	9
48	SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis. IDCases, 2020, 20, e00778.	0.4	8
49	"This is not my bodyâ€! Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis. PLoS ONE, 2021, 16, e0251482.	1.1	8
50	Outcomes of Children Born to Pregnant Women With Drug-resistant Tuberculosis Treated With Novel Drugs in Khayelitsha, South Africa: A Report of Five Patients. Pediatric Infectious Disease Journal, 2021, 40, e191-e192.	1.1	7
51	Tuberculosis Control in Acute Disaster Settings: Case Studies from the 2010 Haiti Earthquake. Disaster Medicine and Public Health Preparedness, 2013, 7, 129-130.	0.7	6
52	The â€~invisibility' of children with tuberculosis. Journal of Public Health Policy, 2015, 36, 123-125.	1.0	6
53	Overcoming Challenges in the Diagnosis, Prevention, and Treatment of Pediatric Drug-Resistant Tuberculosis. Expert Review of Respiratory Medicine, 2017, 11, 385-394.	1.0	6
54	Access to paediatric formulations for the treatment of childhood tuberculosis. The Lancet Child and Adolescent Health, 2020, 4, 855-857.	2.7	6

#	Article	IF	CITATIONS
55	Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis. European Respiratory Journal, 2017, 50, 1701552.	3.1	5
56	Bedaquiline use in South Africa reveals a lifesaving policy in action. Lancet Respiratory Medicine,the, 2018, 6, 653-655.	5.2	5
57	Healthcare Provider Discrimination toward Pregnant Women with Rifampin-Resistant Tuberculosis. Emerging Infectious Diseases, 2019, 25, 609-610.	2.0	5
58	Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline. International Journal of Tuberculosis and Lung Disease, 2017, 21, 4-5.	0.6	4
59	Prevention of hearing loss in patients with multidrug-resistant tuberculosis. Lancet, The, 2017, 390, 934.	6.3	4
60	Reducing harm in the treatment of multidrug-resistant tuberculosis. Lancet, The, 2018, 392, 797-798.	6.3	4
61	The tuberculosis emergency in eastern Europe. Lancet HIV,the, 2016, 3, e107-e108.	2.1	3
62	When it comes to stopping tuberculosis, what is actually "missing�. PLOS Global Public Health, 2022, 2, e0000319.	0.5	3
63	To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2017, 65, 1212-1213.	2.9	2
64	Protecting those who serve: are we doing enough to prevent tuberculosis in healthcare workers?. European Respiratory Journal, 2019, 53, 1900485.	3.1	2
65	Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa― European Respiratory Journal, 2020, 56, 2000837.	3.1	2
66	"Take the treatment and be brave― Care experiences of pregnant women with rifampicin-resistant tuberculosis. PLoS ONE, 2020, 15, e0242604.	1.1	2
67	Implementing a Substance-Use Screening and Intervention Program for People Living with Rifampicin-Resistant Tuberculosis: Pragmatic Experience from Khayelitsha, South Africa. Tropical Medicine and Infectious Disease, 2022, 7, 21.	0.9	2
68	Being heard on all-oral therapy for resistant tuberculosis. Lancet Infectious Diseases, The, 2022, 22, 923-924.	4.6	2
69	Stability of Second-Line Tuberculosis Medications Mixed With Milk or Yogurt. Clinical Infectious Diseases, 2017, 65, 704-705.	2.9	1
70	Bedaquiline or delamanid for rifampin-resistant tuberculosis?. Lancet Respiratory Medicine,the, 2017, 5, 772-774.	5.2	1
71	Treatment of Multidrug-Resistant Tuberculosis in Children and Adolescents. Journal of Pediatric Infectious Diseases, 2018, 13, 153-168.	0.1	1
72	India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further. Lung India, 2021, 38, 590.	0.3	1

#	Article	IF	CITATIONS
73	Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa. Lancet Respiratory Medicine,the, 2022, 10, 542-543.	5.2	1
74	Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods. , 2022, 1, e0000059.		1
75	In reply. QTc prolongation and delamanid: access and safety. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1262-1263.	0.6	0
76	Life in the time of antiretrovirals in South Africa. Lancet HIV,the, 2017, 4, e95-e96.	2.1	0
77	Optimal Management of Drug-Resistant Tuberculosis and Human Immunodeficiency Virus: an Update. Current Treatment Options in Infectious Diseases, 2018, 10, 90-106.	0.8	Ο
78	Providing quality care on the border with Haiti. Lancet, The, 2018, 392, 382.	6.3	0
79	Demanding an end to tuberculosis. Current Opinion in HIV and AIDS, 2019, 14, 21-27.	1.5	0
80	The problem with vitamin D supplementation for tuberculosis. Lancet HIV,the, 2020, 7, e450-e451.	2.1	0
81	Treating Drug-resistant Tuberculosis Infection: No More Excuses. Clinical Infectious Diseases, 2021, 72, 1716-1718.	2.9	Ο
82	The incalculable costs of tuberculosis. The Lancet Global Health, 2021, 9, e1337-e1338.	2.9	0
83	The potential perils of a drug protection framework in tuberculosis. Lancet Infectious Diseases, The, 2021, , .	4.6	0
84	Helping hospitals heal people with HIV and tuberculosis. Lancet HIV,the, 2022, 9, e224-e225.	2.1	0
85	Title is missing!. , 2020, 15, e0242604.		Ο
86	Title is missing!. , 2020, 15, e0242604.		0
87	Title is missing!. , 2020, 15, e0242604.		0
88	Title is missing!. , 2020, 15, e0242604.		0
89	Title is missing!. , 2020, 15, e0242604.		0
90	Title is missing!. , 2020, 15, e0242604.		0